What is MBRX's P/E ratio?

Moleculin Biotech Inc (MBRX) currently trades at a P/E ratio of 0.46.

Moleculin Biotech Inc reports a Return on Equity (ROE) of -199.78%.

What is MBRX's dividend yield?

Moleculin Biotech Inc offers a dividend yield of 0.00%.

What is MBRX's Quality Score?

Our AI rates MBRX's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy MBRX?

Our AI Timing Score for MBRX is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does MBRX belong to?

Moleculin Biotech Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Moleculin Biotech Inc (MBRX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

MBRX AI Analysis Summary

Our AI summary for MBRX: Moleculin Biotech Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.46, ROE of -199.78%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

MBRX

Moleculin Biotech Inc

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 0.40

-0.62 (-60.78%) Day Change

Watchlist Portfolio Compare Chart

0.46

P/E

0.01

D/E

-199.8%

ROE

-129.8%

ROA

0.00%

Div Yield

MOLECULIN BIOTECH INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.40 Price -0.62 (-60.78%) Day Change	NEWS SCORE: N/A

MBRX, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

50%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.40
PBV / Sector	0.47 / 5.20 GREAT
Earning Per Share	-1.68

PE / Sector	0.46 / 19.97 GREAT
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	0.83 M GREAT
Average 1W Daily Value	2.40 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	N/A / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-129.83 / 27.02
ROA Average (%) / Sector	-107.71 / -368.17
ROA Change Average (%) / Sector	30.68 / 5,404.12 GREAT
ROE (%) / Sector	-199.78 / 3.47
ROE Average (%) / Sector	-191.44 / 6.51
ROE Change Average (%) / Sector	68.72 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:09
Symbol	MBRX
Name	MOLECULIN BIOTECH INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	7.07 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	7.21 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 5300 Memorial Drive, Houston, TX, United States, 77007

Phone: 713 300 5160

Website: https://moleculin.com

Sector: Healthcare >> Biotechnology

Description: Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.